Precipio Inc
$ 28.15
-0.53%
20 Apr - close price
- Market Cap 50,478,000 USD
- Current Price $ 28.15
- High / Low $ 28.65 / 27.95
- Stock P/E N/A
- Book Value 8.18
- EPS -0.23
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.04 %
- ROE -0.03 %
- 52 Week High 29.80
- 52 Week Low 5.45
About
Precipio, Inc., a cancer diagnostic and reagent technology company, provides diagnostic products and services in the United States oncology market. The company is headquartered in New Haven, Connecticut.
Analyst Target Price
$19.00
Quarterly Earnings
| Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-02 | 2025-11-14 | 2025-08-13 | 2025-05-12 | 2025-03-31 | 2024-11-11 | 2024-08-13 | 2024-05-14 | 2023-11-13 | 2023-08-11 | 2023-05-12 | 2023-03-30 |
| Reported EPS | 0.2954 | -0.05 | 0.05 | -0.5883 | -0.2444 | -0.4229 | -0.8336 | 0.6514 | -1.04 | -0.09 | -0.13 | -0.1 |
| Estimated EPS | None | None | None | None | 0.74 | None | None | None | -1.21 | -0.1 | -0.13 | -0.14 |
| Surprise | 0 | 0 | 0 | 0 | -0.9844 | 0 | 0 | 0 | 0.17 | 0.01 | 0 | 0.04 |
| Surprise Percentage | None% | None% | None% | None% | -133.027% | None% | None% | None% | 14.0496% | 10% | 0% | 28.5714% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PRPO
2026-04-17 21:39:17
Precipio, Inc. director Christina Rizopoulos Valauri received a grant of 93 shares of common stock on April 15, 2026, as compensation for her service on the Board of Directors for Q1-25. This stock grant, valued at $29.49 per share, was provided in lieu of cash payment. Following this transaction, Valauri directly owns 5,520 shares of Precipio common stock.
2026-04-17 21:10:45
Precipio, Inc. director Jeffrey Cossman received a grant of 365 shares of common stock on April 15, 2026, as compensation for his Q1-26 Board of Directors service. The shares were valued at $29.49 each, increasing his direct holdings to 16,133 shares. This transaction was reported in a Form 4 and was a stock grant in lieu of cash payment.
2026-04-17 21:10:45
Precipio, Inc. director David Seth Cohen received a grant of 445 shares of common stock on April 15, 2026, as compensation for his Q1-26 Board of Directors service. The shares were valued at $29.49 each, totaling approximately $13,000, and were issued in lieu of a cash payment. This transaction increased his direct holdings to 54,679 common shares.
2026-04-14 23:10:34
This article analyzes Precipio Inc. (NASDAQ: PRPO) volatility, presenting a neutral near and mid-term outlook but a positive long-term bias. It outlines institutional trading strategies including position, momentum, and risk-hedging, along with multi-timeframe signal analysis to guide potential trading decisions. The analysis highlights resistance testing and risk-reward setups for the stock.
2026-04-10 20:39:13
Precipio's Chief Operating Officer, Sabet Ahmed Zaki, purchased 19 shares of PRPO common stock for $530 on April 1, 2026. This transaction follows a period of strong stock performance, with a 415% return over the past year. InvestingPro analysis indicates that the company is undervalued and has a "GREAT" Financial Health score, backed by recent Q4 2025 earnings showing a shift to positive cash flow and strong performance in its Pathology Services division.
2026-04-10 19:39:13
Precipio Inc.'s Chief Operating Officer, Ahmed Zaki, purchased 19 shares of common stock at $27.93 per share on April 1, 2026, under a pre-arranged Rule 10b5-1 trading plan. This transaction increased his direct holdings to 1,034 shares. The filing indicates a neutral impact and sentiment regarding this insider trading activity.
